SCHEMBL3635359

SCHEMBL3635359

Fc1cccc(NCc2c[nH]nc2-c2cccs2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
MAPT P10636 6/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
HPGD P15428 2/20 0.40
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
LMNA P02545 1/20 0.39
NTRK1 P04629 1/20 0.39
TP53 P04637 1/20 0.38
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
RXFP1 Q9HBX9 1/20 0.37
ALDH1A1 P00352 3/20 0.37
USP2 O75604 1/20 0.37
GAA P10253 1/20 0.37
ALOX15 P16050 1/20 0.37
ALOX12 P18054 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3638148 0.86 KDM4E (0.47) MAPTHPGDKDM4EMEN1KMT2A
SCHEMBL3635302 0.85 MAPT (0.46) MAPTL3MBTL1KDM4EMEN1KMT2A
SCHEMBL3641293 0.84 POLB (0.46) NOS1MAPTL3MBTL1HPGDKDM4E
SCHEMBL3636897 0.83 FLT1 (0.41) MAPTMEN1KMT2ATP53SMN1; SMN2
SCHEMBL3639036 0.83 GRK2 (0.46) KDM4ELMNAPOLBALDH1A1USP2
SCHEMBL3637833 0.83 NOS1 (0.44) NOS1MAPTKDM4EMEN1KMT2A
SCHEMBL3635764 0.81 MAPT (0.44) MAPTL3MBTL1MEN1KMT2ALMNA
SCHEMBL3640828 0.81 KDM4E (0.47) MAPTKDM4EMEN1KMT2APOLB
SCHEMBL3638150 0.81 ALDH1A1 (0.42) MAPTL3MBTL1HPGDKDM4EMEN1
SCHEMBL3639359 0.81 MAPT (0.40) MAPTHPGDKDM4EKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 NOS1 3729/4885ABCG2 757/4885MAPT 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.